A legitimate online peptide clinic can tell you three things without hedging: the name and state license of the clinician who will prescribe, the name and license of the pharmacy that will fill the order, and whether the drug is FDA-approved, compounded, or neither. If a clinic can't answer all three in writing before you pay, stop there. The rest of this checklist covers labs, pricing, follow-up and the marketing claims that should end the conversation.
Why vetting matters more for peptides than for most telehealth
When you use telehealth for a common, FDA-approved drug, the main risk is a careless prescriber. Peptide therapy adds a second risk: the product itself. Most peptides marketed to men are not FDA-approved for any use. The ones a pharmacy can lawfully prepare are compounded, and compounded drugs skip FDA's premarket review of safety, effectiveness and manufacturing quality. Then there is a third channel, "research use only" vials, which aren't sold for human use at all.
A clinic can move you between those three channels without saying so. That is why the checklist below starts with people and paperwork rather than price. If you want the bigger map of those channels first, read our research vs prescribed vs brand sourcing map.
Before you book anything, email the clinic: (1) Who will prescribe, and in which states are they licensed? (2) Which pharmacy fills the prescription, and is it a 503A pharmacy or a 503B outsourcing facility? (3) Is the drug FDA-approved, and if it's compounded, on what legal basis? Vague answers to any one of these is your answer.
The 12-point checklist
1. A named prescriber licensed in your state
Telehealth prescribers generally need a license in the state where you are physically located during the visit. A real clinic will tell you the clinician's name and credential (MD, DO, NP or PA) before or during the visit. Look the license up yourself on your state medical or nursing board's public lookup. It takes two minutes and shows disciplinary history.
2. An actual evaluation, not an auto-approval
A questionnaire that ends in "Approved!" within seconds isn't an evaluation. You want a clinician who reviews your history, medications and labs, and who can say no. FDA's own consumer warning about online weight-loss drug sellers lists "no required doctor screening" as a red flag, and the same logic applies to peptides.
3. Baseline labs, and a plan for repeat labs
Ask which labs are required before the first prescription and how often they repeat. For anything that touches the testosterone or growth-hormone axis, a clinic that never orders bloodwork isn't managing risk. For reference, the American Urological Association's testosterone guideline calls for two early-morning total testosterone measurements on separate days before diagnosing deficiency, plus LH, and hemoglobin and hematocrit before starting therapy. Our bloodwork guide explains what the common panels show.
4. A plain statement of what the drug is
Every prescription falls into one of three categories:
- FDA-approved product (for example, tesamorelin as Egrifta, or brand semaglutide). It has a label, a manufacturer and an approved indication.
- Compounded preparation made by a licensed pharmacy for you. It is not FDA-approved, and its quality depends on the pharmacy.
- A "research" product with no lawful human-use pathway. A clinic shouldn't be routing you here at all.
Ask the clinic to put the category in writing. "Pharmaceutical grade" and "physician formulated" are marketing phrases, not categories.
5. A legal basis for compounding that specific peptide
Compounding isn't a blank check. Under section 503A, a pharmacy may only start from bulk ingredients that are part of an FDA-approved drug, have a USP or NF monograph, or appear on FDA's 503A bulks list. Some peptides are shut out entirely. FDA's position is that biological products, a category that since March 2020 includes human chorionic gonadotropin (hCG) and tesamorelin, are not eligible for the compounding exemptions. And a favorable advisory-committee vote, like the July 2026 one on BPC-157, doesn't put a substance on the bulks list by itself. Our 503A bulks list explainer walks through the steps.
6. A named, licensed pharmacy
Get the pharmacy's name and address before you pay. Then check two things: that it holds a license (or nonresident license) in your state through the state board of pharmacy, and whether it's a 503A pharmacy or a 503B outsourcing facility. FDA publishes a list of registered outsourcing facilities. A clinic that won't name its pharmacy is asking you to trust a black box.
7. A proper label on what arrives
A dispensed prescription should carry your name, the prescriber, the drug and strength, the pharmacy's name and address, and a beyond-use date. FDA's consumer page on unapproved GLP-1 drugs lists misspelled labels and incorrect pharmacy addresses among the warning signs. A vial labeled "for research use only" that arrives through a clinic is a hard stop.
8. Controlled-substance rules handled correctly
Testosterone is a federally controlled substance, so TRT-adjacent clinics have extra rules. DEA and HHS have extended the pandemic-era telemedicine flexibilities, which let DEA-registered practitioners prescribe Schedule II–V drugs without a prior in-person exam, through December 31, 2026. What happens after that depends on rulemaking that hasn't been finalized. Ask the clinic what its plan is if the flexibilities lapse.
9. Pricing you can read before checkout
You don't need a cheap clinic. You need a clear one. Ask what the fee covers: the consult, labs, the medication, supplies, shipping and follow-up visits. Ask whether it's a subscription that renews automatically, how to cancel, and what happens to medication already shipped. Pharmacies generally can't take dispensed medication back, so "cancel anytime" may not mean "refund anytime."
10. Follow-up and a way to reach a clinician
Ask how you report a side effect, who answers, and how fast. A clinic that only offers a billing inbox isn't providing ongoing care. You also want to know who adjusts or stops therapy, and whether that requires another paid visit.
11. Marketing that stays inside the evidence
Walk away from any clinic that calls a compounded drug "FDA-approved", calls it "the same as" a brand product, promises specific results, or sells research-labeled peptides with dosing instructions. FDA has issued warning letters to companies selling GLP-1 compounds labeled "for research purposes" or "not for human consumption" alongside dosing directions. Deep discounts that look too good are on FDA's red-flag list too.
12. Your records and your data
You should be able to download your lab results and visit notes. Read the privacy policy for whether your health information is shared with advertising partners. Third-party certification for telehealth and pharmacies, such as LegitScript, is a plus, but confirm it on the certifier's own site rather than trusting a badge.
Green flags vs red flags at a glance
| Check | Green flag | Red flag |
|---|---|---|
| Prescriber | Named clinician, license you can verify | "Our medical team" with no names |
| Evaluation | History review, labs, can decline you | Instant approval from a form |
| Drug status | Written: approved, or compounded with a stated basis | "Pharmaceutical grade", "same as brand" |
| Pharmacy | Named, licensed in your state, 503A or 503B stated | Unnamed "partner pharmacy" |
| Pricing | Line items, renewal terms, cancellation in writing | Price only shown after card entry |
| Follow-up | Clinician messaging, side-effect process | Billing inbox only |
| Claims | Evidence described honestly, risks listed | Guaranteed results, before/after promises |
Questions to copy into your first message
- What is the full name and license state of the clinician who will review my case?
- Which labs do you require before prescribing, and how often do you repeat them?
- Is the medication FDA-approved or compounded? If compounded, which pharmacy makes it, and is it 503A or 503B?
- Is that pharmacy licensed to ship to my state?
- What does the monthly fee include, does it auto-renew, and how do I cancel?
- If I have a side effect, who do I contact and how quickly will a clinician respond?
A good clinic answers these in one reply. If the answers come back as sales copy, you've learned what you needed to know.
Where a prescription pathway fits
For men interested in prescription peptides with an actual approval history, sermorelin and tesamorelin are the usual starting points. Our sermorelin online guide covers who prescribes it and what drives the cost. If you'd rather start with a telehealth service that puts a clinician in charge of that decision, this is the one we link to:
Dosing for prescription peptides is set by the prescribing clinician. Research-use-only peptides are not sold for human use and have no approved human dose. See our medical disclaimer.
Chest pain, shortness of breath, severe headache, vision changes, a swollen or painful injection-site infection, or symptoms of an allergic reaction need same-day in-person care, not a portal message.
Sources
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026): red flags, research-labeled product warnings, BeSafeRx.
- FDA, Information for outsourcing facilities: 503B registration, CGMP, risk-based inspection, product reporting.
- FDA, Notice to compounders on the March 23, 2020 biologics transition, and the list of NDAs deemed to be BLAs (includes chorionic gonadotropin and tesamorelin).
- American Urological Association, Evaluation and Management of Testosterone Deficiency (2018, validity confirmed 2024).
- McDermott+, DEA extends telemedicine flexibilities for controlled substance prescribing for 2026.
Frequently Asked
Ask for the prescriber's name and state license, the name and license of the dispensing pharmacy, and whether the drug is FDA-approved or compounded. Verify the licenses yourself on your state boards' lookup tools. A clinic that won't put those answers in writing before you pay isn't one to use.
No. Compounded preparations are made by a licensed pharmacy for an individual patient and do not go through FDA's premarket review for safety, effectiveness or manufacturing quality. That doesn't automatically make them unsafe, but it means the pharmacy's quality controls matter a lot.
Under the DEA and HHS telemedicine flexibilities, DEA-registered practitioners can prescribe Schedule II to V controlled substances, including testosterone, without a prior in-person exam through December 31, 2026. What happens after that depends on federal rulemaking that had not been finalized as of this writing.
It depends on the drug, but anything that affects testosterone or growth hormone should involve baseline bloodwork. The AUA testosterone guideline, for example, calls for two early-morning testosterone measurements, an LH level, and hemoglobin and hematocrit before therapy starts.
Yes. Research-use-only products are not sold for human use and have no approved human dose. A clinic dispensing them to patients is operating outside the prescription system, and FDA has issued warning letters to sellers doing exactly that.